Although the effectiveness of the IgA antibody isotype as a potential neutralizing monoclonal antibody in mitigating COVID-19 already have reported, but its exact molecular mechanism of action, particularly against SARS-CoV-2 remains unclear [[22], [23], [24], [25], [26]]. This evidence concerns the gene CD79A and COVID-19.